Crossref
journal-article
Elsevier BV
Clinical Oncology (78)
References
160
Referenced
79
10.1016/S0020-7292(03)90118-4/ Int J Gynaecol Obstet / Carcinoma of the ovary by Heintz (2003){'key': '10.1016/j.clon.2005.05.009_bib2', 'series-title': 'GLOBCAN 2000: Cancer incidence, mortality and prevalence worldwide', 'author': 'Ferlay', 'year': '2001'}/ GLOBCAN 2000: Cancer incidence, mortality and prevalence worldwide by Ferlay (2001)- SEER: Surveillance, Epidemiology, and End Results Program [computer program]. 2003.
10.1093/oxfordjournals.aje.a116429/ Am J Epidemiol / Characteristics relating to ovarian cancer risk: collaborative analysis of 12 US case–control studies. IV. The pathogenesis of epithelial ovarian cancer. Collaborative Ovarian Cancer Group by Whittemore (1992)10.1093/oxfordjournals.aje.a117055/ Am J Epidemiol / A case–control study of oral contraceptive use and invasive epithelial ovarian cancer by Rosenberg (1994)10.1038/bjc.1995.260/ Br J Cancer / Endometrial and ovarian cancer and oral contraceptives: findings in a large cohort study by Vessey (1995)10.1093/aje/152.3.233/ Am J Epidemiol / Risk of ovarian cancer in relation to estrogen and progestin dose and use characteristics of oral contraceptives. SHARE Study Group. Steroid Hormones and Reproductions by Ness (2000)10.1002/1097-0142(19950715)76:2<284::AID-CNCR2820760219>3.0.CO;2-5/ Cancer / A prospective study of reproductive factors and risk of epithelial ovarian cancer by Hankinson (1995){'key': '10.1016/j.clon.2005.05.009_bib9', 'first-page': '265', 'article-title': 'Breast and ovarian cancer incidence in BRCA1-mutation carriers. Breast Cancer Linkage Consortium', 'volume': '56', 'author': 'Easton', 'year': '1995', 'journal-title': 'Am J Hum Genet'}/ Am J Hum Genet / Breast and ovarian cancer incidence in BRCA1-mutation carriers. Breast Cancer Linkage Consortium by Easton (1995)10.1016/S0140-6736(02)11023-3/ Lancet / Risk of ovarian cancer in breast-cancer patients with a family history of breast or ovarian cancer: a population-based cohort study by Bergfeldt (2002)10.1016/S0029-7844(98)00139-2/ Obstet Gynecol / Hormone replacement therapy and the risk of epithelial ovarian carcinoma: a meta-analysis by Garg (1998)10.1001/jama.285.11.1460/ JAMA / Estrogen replacement therapy and ovarian cancer mortality in a large prospective study of US women by Rodriguez (2001)10.1001/jama.290.13.1739/ JAMA / Effects of estrogen plus progestin on gynecologic cancers and associated diagnostic procedures: the Women's Health Initiative randomized trial by Anderson (2003)10.1002/ijc.2910620606/ Int J Cancer / Reproductive and other factors and risk of epithelial ovarian cancer: an Australian case–control study. Survey of Women's Health Study Group by Purdie (1995){'key': '10.1016/j.clon.2005.05.009_bib15', 'first-page': '447', 'article-title': 'Pelvic inflammatory disease and the risk of epithelial ovarian cancer', 'volume': '4', 'author': 'Risch', 'year': '1995', 'journal-title': 'Cancer Epidemiol Biomarkers Prev'}/ Cancer Epidemiol Biomarkers Prev / Pelvic inflammatory disease and the risk of epithelial ovarian cancer by Risch (1995)10.1016/0029-7844(96)00226-8/ Obstet Gynecol / Epithelial ovarian cancer risk among women with polycystic ovary syndrome by Schildkraut (1996)10.1093/oxfordjournals.aje.a115249/ Am J Epidemiol / Association of obesity and ovarian cancer in a case–control study by Farrow (1989){'key': '10.1016/j.clon.2005.05.009_bib18', 'first-page': '663', 'article-title': 'Dietary factors and the risk of epithelial ovarian cancer', 'volume': '79', 'author': 'La Vecchia', 'year': '1987', 'journal-title': 'J Natl Cancer Inst'}/ J Natl Cancer Inst / Dietary factors and the risk of epithelial ovarian cancer by La Vecchia (1987){'key': '10.1016/j.clon.2005.05.009_bib19', 'first-page': '1955', 'article-title': 'Perineal application of cosmetic talc and risk of invasive epithelial ovarian cancer: a meta-analysis of 11,933 subjects from sixteen observational studies', 'volume': '23', 'author': 'Huncharek', 'year': '2003', 'journal-title': 'Anticancer Res'}/ Anticancer Res / Perineal application of cosmetic talc and risk of invasive epithelial ovarian cancer: a meta-analysis of 11,933 subjects from sixteen observational studies by Huncharek (2003)10.1016/S0140-6736(99)05203-4/ Lancet / Risk of cancer after use of fertility drugs with in-vitro fertilisation by Venn (1999)10.1200/JCO.1991.9.7.1138/ J Clin Oncol / Long-term follow-up and prognostic factor analysis in advanced ovarian carcinoma: the Gynecologic Oncology Group experience by Omura (1991)10.1200/JCO.2004.08.078/ J Clin Oncol / Mucinous epithelial ovarian cancer: a separate entity requiring specific treatment by Hess (2004)10.1016/S0140-6736(00)03590-X/ Lancet / Prognostic importance of degree of differentiation and cyst rupture in stage I invasive epithelial ovarian carcinoma by Vergote (2001)10.1136/bmj.306.6884.1030/ BMJ / Prevalence screening for ovarian cancer in postmenopausal women by CA 125 measurement and ultrasonography by Jacobs (1993)10.1586/14737159.2.4.312/ Expert Rev Mol Diagn / Clinical potential of proteomics in the diagnosis of ovarian cancer by Ardekani (2002)10.1086/375033/ Am J Hum Genet / Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history: a combined analysis of 22 studies by Antoniou (2003)10.1006/gyno.2002.6674/ Gynecol Oncol / Specific keynote: hereditary ovarian cancer: what we know by Boyd (2003)10.1001/jama.1997.03540360065034/ JAMA / Recommendations for follow-up care of individuals with an inherited predisposition to cancer. II. BRCA1 and BRCA2. Cancer Genetics Studies Consortium by Burke (1997)10.1200/JCO.2004.07.179/ J Clin Oncol / Biology of epithelial ovarian cancer: implications for screening women at high genetic risk by Hogg (2004)10.1056/NEJMoa012158/ N Engl J Med / Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations by Rebbeck (2002){'key': '10.1016/j.clon.2005.05.009_bib31', 'first-page': '703', 'article-title': 'CA125 antigen levels in obstetric and gynecologic patients', 'volume': '64', 'author': 'Niloff', 'year': '1984', 'journal-title': 'Obstet Gynecol'}/ Obstet Gynecol / CA125 antigen levels in obstetric and gynecologic patients by Niloff (1984)10.1056/NEJM198310133091503/ N Engl J Med / A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer by Bast (1983)10.1111/j.1471-0528.1990.tb02448.x/ Br J Obstet Gynaecol / A risk of malignancy index incorporating CA 125, ultrasound and menopausal status for the accurate preoperative diagnosis of ovarian cancer by Jacobs (1990)10.1006/gyno.1996.0025/ Gynecol Oncol / Preoperative evaluation of D-dimer and CA 125 levels in differentiating benign from malignant ovarian masses by Gadducci (1996)10.1006/gyno.1995.1276/ Gynecol Oncol / Combinations of multiple serum markers are superior to individual assays for discriminating malignant from benign pelvic masses by Woolas (1995)10.1006/gyno.2000.5768/ Gynecol Oncol / Classification of asymptomatic adnexal masses by ultrasound, magnetic resonance imaging, and positron emission tomography by Grab (2000)10.1148/radiology.212.1.r99jl3619/ Radiology / Diagnosis and staging of ovarian cancer: comparative values of Doppler and conventional US, CT, and MR imaging correlated with surgery and histopathologic analysis: analysis report of the Radiology Diagnostic Oncology Group by Kurtz (1999)10.1200/JCO.2003.01.223/ J Clin Oncol / Use of CA-125 to assess response to new agents in ovarian cancer trials by Rustin (2003)10.1038/bjc.1994.307/ Br J Cancer / Management of ovarian cancer: referral to a multidisciplinary team matters by Junor (1994)10.1006/gyno.1997.4884/ Gynecol Oncol / Quantitative prognostic features in FIGO I ovarian cancer patients without postoperative treatment by Brugghe (1998)10.1016/0029-7844(95)00126-C/ Obstet Gynecol / Preoperative CA 125: an independent prognostic factor in patients with stage I epithelial ovarian cancer by Nagele (1995)10.1023/A:1008399414923/ Ann Oncol / Randomized study on adjuvant chemotherapy in stage I high-risk ovarian cancer with evaluation of DNA-ploidy as prognostic instrument by Trope (2000)10.1093/jnci/95.2.113/ J Natl Cancer Inst / Impact of adjuvant chemotherapy and surgical staging in early-stage ovarian carcinoma: European Organisation for Research and Treatment of Cancer-Adjuvant ChemoTherapy in Ovarian Neoplasm trial by Trimbos (2003)10.1006/gyno.2002.6805/ Gynecol Oncol / Outcome of reproductive age women with stage IA or IC invasive epithelial ovarian cancer treated with fertility-sparing therapy by Schilder (2002)10.1111/j.1471-0528.1997.tb12062.x/ Br J Obstet Gynaecol / Conservative surgery for stage I ovarian carcinoma in women of childbearing age by Zanetta (1997)10.1056/NEJM199004123221501/ N Engl J Med / Adjuvant therapy in stage I and stage II epithelial ovarian cancer. Results of two prospective randomized trials by Young (1990)10.1200/JCO.1996.14.11.2968/ J Clin Oncol / Natural history and prognosis of untreated stage I epithelial ovarian carcinoma by Ahmed (1996)10.1093/jnci/95.2.125/ J Natl Cancer Inst / International Collaborative Ovarian Neoplasm trial 1: a randomized trial of adjuvant chemotherapy in women with early-stage ovarian cancer by Colombo (2003)10.1200/JCO.1985.3.7.901/ J Clin Oncol / Postoperative radiation therapy for epithelial ovarian cancer: the curative role based on a 24-year experience by Martinez (1985)10.1002/1097-0142(19920201)69:3<741::AID-CNCR2820690322>3.0.CO;2-G/ Cancer / Randomized trial comparing cisplatin with radioactive phosphorus or whole-abdomen irradiation as adjuvant treatment of ovarian cancer by Vergote (1992)10.1200/JCO.2003.02.154/ J Clin Oncol / Adjuvant treatment for early ovarian cancer: a randomized phase III trial of intraperitoneal 32P or intravenous cyclophosphamide and cisplatin: a gynecologic oncology group study by Young (2003){'key': '10.1016/j.clon.2005.05.009_bib52', 'first-page': '101', 'article-title': 'Surgical resection of tumor bulk in the primary treatment of ovarian carcinoma', 'volume': '42', 'author': 'Griffiths', 'year': '1975', 'journal-title': 'Natl Cancer Inst Monogr'}/ Natl Cancer Inst Monogr / Surgical resection of tumor bulk in the primary treatment of ovarian carcinoma by Griffiths (1975)10.1016/0090-8258(92)90100-W/ Gynecol Oncol / The influence of cytoreductive surgery on recurrence-free interval and survival in small-volume stage III epithelial ovarian cancer: a Gynecologic Oncology Group study by Hoskins (1992)10.1016/S0002-9378(15)33580-8/ Am J Obstet Gynecol / The changing prognosis and treatment in cancer of the ovary. A report of 235 patients with primary ovarian carcinoma 1952–1961 by Munnell (1968)10.1200/JCO.20.5.1248/ J Clin Oncol / Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis by Bristow (2002)10.1111/j.1471-0528.1999.tb08137.x/ Br J Obstet Gynaecol / Specialist gynaecologists and survival outcome in ovarian cancer: a Scottish national study of 1866 patients by Junor (1999)10.1006/gyno.1998.5236/ Gynecol Oncol / Neoadjuvant chemotherapy for advanced ovarian cancer: long-term survival by Schwartz (1999)10.1006/gyno.1998.5213/ Gynecol Oncol / Neoadjuvant chemotherapy or primary debulking surgery in advanced ovarian carcinoma: a retrospective analysis of 285 patients by Vergote (1998)10.1056/NEJM199503093321002/ N Engl J Med / The effect of debulking surgery after induction chemotherapy on the prognosis in advanced epithelial ovarian cancer. Gynecological Cancer Cooperative Group of the European Organization for Research and Treatment of Cancer by van der Burg (1995){'key': '10.1016/j.clon.2005.05.009_bib60', 'first-page': '21', 'article-title': 'A phase III randomised study of interval secondary cytoreduction in patients with advanced stage ovarian carcinoma with suboptimal residual disease: a Gynecologic Oncology Group study', 'author': 'Rose', 'year': '2002', 'journal-title': 'Proc Am Soc Clin Oncol'}/ Proc Am Soc Clin Oncol / A phase III randomised study of interval secondary cytoreduction in patients with advanced stage ovarian carcinoma with suboptimal residual disease: a Gynecologic Oncology Group study by Rose (2002)10.1016/S0090-8258(03)00342-1/ Gynecol Oncol / Future directions in the surgical management of ovarian cancer by Berman (2003)10.1016/j.ygyno.2003.08.036/ Gynecol Oncol / Long-term follow-up of women with ovarian cancer after positive second-look laparotomy by Dowdy (2003)10.1016/S0029-7844(98)00334-2/ Obstet Gynecol / Ten-year follow-up of ovarian cancer patients after second-look laparotomy with negative findings by Rubin (1999)10.1002/1097-0142(19860501)57:9<1725::AID-CNCR2820570903>3.0.CO;2-J/ Cancer / A randomized trial of cyclophosphamide and doxorubicin with or without cisplatin in advanced ovarian carcinoma. A Gynecologic Oncology Group Study by Omura (1986)10.1200/JCO.1985.3.11.1455/ J Clin Oncol / Cisplatin combination chemotherapy versus chlorambucil in advanced ovarian carcinoma: mature results of a randomized trial by Williams (1985)10.1038/bjc.1998.710/ Br J Cancer / Chemotherapy in advanced ovarian cancer: four systematic meta-analyses of individual patient data from 37 randomized trials. Advanced Ovarian Cancer Trialists' Group by Aabo (1998)10.1200/JCO.2003.02.153/ J Clin Oncol / Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study by Ozols (2003)10.1093/jnci/djg036/ J Natl Cancer Inst / A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer by du Bois (2003)10.1200/JCO.1992.10.5.706/ J Clin Oncol / Improved therapeutic index of carboplatin plus cyclophosphamide versus cisplatin plus cyclophosphamide: final report by the Southwest Oncology Group of a phase III randomized trial in stages III and IV ovarian cancer by Alberts (1992)10.1200/JCO.1992.10.5.718/ J Clin Oncol / Cisplatin–cyclophosphamide versus carboplatin–cyclophosphamide in advanced ovarian cancer: a randomized phase III study of the National Cancer Institute of Canada Clinical Trials Group by Swenerton (1992)10.1200/JCO.1996.14.7.2113/ J Clin Oncol / Mature results of a randomized trial of two doses of cisplatin for the treatment of ovarian cancer. Scottish Gynecology Cancer Trials Group by Kaye (1996)10.1200/JCO.1995.13.7.1589/ J Clin Oncol / Assessment of dose-intensive therapy in suboptimally debulked ovarian cancer: a Gynecologic Oncology Group study by McGuire (1995)10.1200/JCO.1998.16.7.2426/ J Clin Oncol / Randomized trial of dose-intensity with single-agent carboplatin in patients with epithelial ovarian cancer. London Gynaecological Oncology Group by Gore (1998)10.1023/A:1008256431090/ Ann Oncol / A randomized trial of five versus eight courses of cisplatin or carboplatin in advanced epithelial ovarian carcinoma. A North Thames Ovary Group Study by Lambert (1997)10.1200/JCO.1991.9.9.1668/ J Clin Oncol / Cyclophosphamide plus cisplatin versus cyclophosphamide, doxorubicin, and cisplatin chemotherapy of ovarian carcinoma: a meta-analysis. The Ovarian Cancer Meta-Analysis Project (1991)10.1016/S0140-6736(98)04119-1/ Lancet / ICON2: randomised trial of single-agent carboplatin against three-drug combination of CAP (cyclophosphamide, doxorubicin, and cisplatin) in women with ovarian cancer. ICON Collaborators. International Collaborative Ovarian Neoplasm Study (1998)10.1056/NEJM199601043340101/ N Engl J Med / Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer by McGuire (1996)10.1093/jnci/92.9.699/ J Natl Cancer Inst / Randomized intergroup trial of cisplatin–paclitaxel versus cisplatin–cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results by Piccart (2000)10.1200/JCO.2000.18.1.106/ J Clin Oncol / Phase III randomized study of cisplatin versus paclitaxel versus cisplatin and paclitaxel in patients with suboptimal stage III or IV ovarian cancer: a gynecologic oncology group study by Muggia (2000)10.1016/S0140-6736(02)09738-6/ Lancet / Paclitaxel plus carboplatin versus standard chemotherapy with either single-agent carboplatin or cyclophosphamide, doxorubicin, and cisplatin in women with ovarian cancer: the ICON3 randomised trial (2002){'key': '10.1016/j.clon.2005.05.009_bib81', 'series-title': 'Guidance on the use of paclitaxel in the treatment of ovarian cancer', 'author': 'NICE', 'year': '2003'}/ Guidance on the use of paclitaxel in the treatment of ovarian cancer by NICE (2003)10.1046/j.1525-1438.2002.01118.x/ Int J Gynecol Cancer / Docetaxel in combination with carboplatin for chemo-naive patients with epithelial ovarian cancer by Aoki (2002)10.1200/JCO.2001.19.7.1901/ J Clin Oncol / Combination chemotherapy with carboplatin and docetaxel in the treatment of cancers of the ovary and fallopian tube and primary carcinoma of the peritoneum by Markman (2001)10.1046/j.1525-1438.2003.13203.x/ Int J Gynecol Cancer / Phase II clinical trial of carboplatin and docetaxel in patients with metastatic ovarian cancer: active combination with low incidence of peripheral neuropathy by Vorobiof (2003){'key': '10.1016/j.clon.2005.05.009_bib85', 'first-page': '201a', 'article-title': 'Survival and longer-term toxicity results from the SCOTROC study; docetaxel–carboplatin (DC) vs. paclitaxel–carboplatin (PC) in epithelial ovarian cancer (EOC)', 'volume': '21', 'author': 'Vasey', 'year': '2002', 'journal-title': 'Proc Am Soc Clin Oncol'}/ Proc Am Soc Clin Oncol / Survival and longer-term toxicity results from the SCOTROC study; docetaxel–carboplatin (DC) vs. paclitaxel–carboplatin (PC) in epithelial ovarian cancer (EOC) by Vasey (2002)10.1093/jnci/86.20.1517/ J Natl Cancer Inst / Computerized quantitation of synergism and antagonism of taxol, topotecan, and cisplatin against human teratocarcinoma cell growth: a rational approach to clinical protocol design by Chou (1994){'key': '10.1016/j.clon.2005.05.009_bib87', 'first-page': '72', 'article-title': 'Interaction between cisplatin and gemcitabine in vitro and in vivo', 'volume': '22', 'author': 'Peters', 'year': '1995', 'journal-title': 'Semin Oncol'}/ Semin Oncol / Interaction between cisplatin and gemcitabine in vitro and in vivo by Peters (1995){'key': '10.1016/j.clon.2005.05.009_bib88', 'article-title': 'Gemcitabine, carboplatin and paclitaxel (GCP) as first-line treatment of ovarian cancer FIGO stages IIB–IV', 'author': 'Hansen', 'year': '1999', 'journal-title': 'Proc Am Soc Clin Oncol'}/ Proc Am Soc Clin Oncol / Gemcitabine, carboplatin and paclitaxel (GCP) as first-line treatment of ovarian cancer FIGO stages IIB–IV by Hansen (1999)- Look KY, Bookman MA, Brady MF, Schol J, Herzog t, Rocerto TF. An update of the phase I feasibility trial of carboplatin, paclitaxel and gemcitabine in patients with previously untreated epithelial ovarian cancer or primary peritoneal cancer (EOC/PPC): a Gynecologic Oncology Group (GOG) study. Proceeding of the 32nd Annual meeting of the society of Gynecologic Oncologists 2001.
10.1200/JCO.2004.04.181/ Proc Am Soc Clin Oncol by Pfisterer (2003)-
du Bois A, Combe M, Rochon J, Jackisch C, Malaurie M, Lueck HJ. Epirubicin/paclitaxel/carboplatin (TEC) vs paclitaxel/carboplatin (TC) in first-line treatment of ovarian cancer (OC) FIGO stages IIB–IV. An AGO-GINECO Intergroup phase III trial [abstract 5007]. ASCO Annual Meeting Proceedings (Post-Meeting Edition) 2004;22:14S.
(
10.1200/jco.2004.22.90140.5007) 10.1111/j.1525-1438.2003.13363.x/ Int J Gynecol Cancer / First-line treatment of ovarian cancer FIGO stages IIb–IV with paclitaxel/epirubicin/carboplatin versus paclitaxel/carboplatin by Kristensen (2003){'key': '10.1016/j.clon.2005.05.009_bib93', 'first-page': '21a', 'article-title': 'Preliminary results of SCOTROC 2A, a randomised feasibility study of carboplatin then sequential docetaxel or two schedules of docetaxel+gemcitabine in ovarian/mullarian cancers', 'author': 'Rustin', 'year': '2002', 'journal-title': 'Proc Am Soc Clin Oncol'}/ Proc Am Soc Clin Oncol / Preliminary results of SCOTROC 2A, a randomised feasibility study of carboplatin then sequential docetaxel or two schedules of docetaxel+gemcitabine in ovarian/mullarian cancers by Rustin (2002)10.1038/sj.bjc.6601618/ Br J Cancer / A phase II study of sequential carboplatin, paclitaxel and topotecan in patients with previously untreated advanced ovarian cancer by Guppy (2004)10.1023/A:1011136807190/ Ann Oncol / High-dose chemotherapy for ovarian carcinoma: long-term results from the Solid Tumour Registry of the European Group for Blood and Marrow Transplantation (EBMT) by Ledermann (2001){'key': '10.1016/j.clon.2005.05.009_bib96', 'first-page': '204a', 'article-title': 'Phase III randomised trial of high-dose chemotherapy (HDC) and peripheral blood stem cell (PBSC) support as consolidation in patients with responsive low-burden advanced ovarian cancer (AOC): Preliminary results of a GINECO/FN-CLCC/SFGM-TC study', 'volume': '20', 'author': 'Cure', 'year': '2001', 'journal-title': 'Proc Am Soc Clin Oncol'}/ Proc Am Soc Clin Oncol / Phase III randomised trial of high-dose chemotherapy (HDC) and peripheral blood stem cell (PBSC) support as consolidation in patients with responsive low-burden advanced ovarian cancer (AOC): Preliminary results of a GINECO/FN-CLCC/SFGM-TC study by Cure (2001)10.1177/030089160108700407/ Tumori / Consolidation radiation therapy following cytoreductive surgery, chemotherapy and second-look laparotomy for epithelial ovarian carcinoma: long-term follow-up by Goldberg (2001)10.1200/JCO.1993.11.3.440/ J Clin Oncol / A randomized trial comparing single-agent carboplatin with carboplatin followed by radiotherapy for advanced ovarian cancer: a North Thames Ovary Group study by Lambert (1993)10.1016/S0936-6555(05)80210-9/ Clin Oncol / A randomized trial comparing whole abdominal radiotherapy with chemotherapy following cisplatinum cytoreduction in epithelial ovarian cancer. West Midlands Ovarian Cancer Group Trial II by Lawton (1990)10.1111/j.1525-1438.2003.13360.x/ Int J Gynecol Cancer / Intraperitoneal cisplatin versus no further treatment: 8-year results of EORTC 55875, a randomized phase III study in ovarian cancer patients with a pathologically complete remission after platinum-based intravenous chemotherapy by Piccart (2003)10.1200/JCO.2003.11.018/ J Clin Oncol / Intraperitoneal radioactive phosphorus (32P) versus observation after negative second-look laparotomy for stage III ovarian carcinoma: a randomized trial of the Gynecologic Oncology Group by Varia (2003)-
Seiden M, Benigno B. A pivotal phase III trial to evaluate the efficacy and safety of adjuvant treatment with R1549 (yttrium-90-labeled HMFG1 murine monoclonal antibody) in epithelial ovarian cancer (EOC) [abstract 5008]. 2004 ASCO Annual Meetings Proceedings (Post-meeting Edition) 2004;22:14S.
(
10.1200/jco.2004.22.14_suppl.5008) 10.1046/j.1525-1438.2000.99510.x/ Int J Gynecol Cancer / Long term survival of patients with advanced ovarian cancer treated with intraperitoneal radioimmunotherapy by Epenetos (2000)10.1006/gyno.2001.6274/ Gynecol Oncol / Phase II trial of oral altretamine for consolidation of clinical complete remission in women with stage III epithelial ovarian cancer: a Southwest Oncology Group trial (SWOG-9326) by Rothenberg (2001)10.1016/S0090-8258(02)00100-2/ Gynecol Oncol / Phase II trial of single agent carboplatin followed by dose-intense paclitaxel, followed by maintenance paclitaxel therapy in stage IV ovarian, fallopian tube, and peritoneal cancers: a Southwest Oncology Group trial by Markman (2003)10.1016/0090-8258(92)90305-3/ Gynecol Oncol / Randomized prospective trial of 5 versus 10 cycles of cyclophosphamide, doxorubicin, and cisplatin in advanced ovarian carcinoma by Hakes (1992)10.1006/gyno.2001.6489/ Gynecol Oncol / Tamoxifen therapy for ovarian cancer in the adjuvant and advanced settings: systematic review of the literature and implications for future research by Perez-Gracia (2002){'key': '10.1016/j.clon.2005.05.009_bib108', 'first-page': '386a', 'article-title': 'Maintenance therapy with interferon for advanced ovarian cancer', 'volume': '19', 'author': 'Hall', 'year': '2000', 'journal-title': 'Proc Am Soc Clin Oncol'}/ Proc Am Soc Clin Oncol / Maintenance therapy with interferon for advanced ovarian cancer by Hall (2000)10.1200/JCO.2003.07.013/ J Clin Oncol / Phase III randomized trial of 12 versus 3 months of maintenance paclitaxel in patients with advanced ovarian cancer after complete response to platinum and paclitaxel-based chemotherapy: a Southwest Oncology Group and Gynecologic Oncology Group trial by Markman (2003)10.1016/S1470-2045(03)01074-X/ Lancet Oncol / Intraperitoneal antineoplastic drug delivery: rationale and results by Markman (2003)10.1056/NEJM199612263352603/ N Engl J Med / Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer by Alberts (1996)10.1006/gyno.1999.5677/ Gynecol Oncol / Intraperitoneal versus intravenous cisplatin in combination with intravenous cyclophosphamide and epidoxorubicin in optimally cytoreduced advanced epithelial ovarian cancer: a randomized trial of the Gruppo Oncologico Nord-Ovest by Gadducci (2000)10.1006/gyno.1994.1220/ Gynecol Oncol / A comparison of intravenous versus intraperitoneal chemotherapy for the initial treatment of ovarian cancer by Kirmani (1994)10.1200/JCO.2001.19.4.1001/ J Clin Oncol by Markman (2001)10.1159/000011980/ Oncology / A comparative study of intraperitoneal carboplatin versus intravenous carboplatin with intravenous cyclophosphamide in both arms as initial chemotherapy for stage III ovarian cancer by Polyzos (1999)10.1016/S0020-7292(00)00340-4/ Int J Gynaecol Obstet / Intraperitoneal cisplatin-based chemotherapy vs. intravenous cisplatin-based chemotherapy for stage III optimally cytoreduced epithelial ovarian cancer by Yen (2001)10.1093/oxfordjournals.annonc.a010602/ Ann Oncol / Defining progression of ovarian carcinoma during follow-up according to CA 125: a North Thames Ovary Group Study by Rustin (1996)10.1093/jnci/92.18.1534/ J Natl Cancer Inst / Re: new guidelines to evaluate the response to treatment in solid tumors [ovarian cancer]. Gynecologic Cancer Intergroup by Vergote (2000)10.1016/S0090-8258(03)00336-6/ Gynecol Oncol / Clinically occult recurrent ovarian cancer: patient selection for secondary cytoreductive surgery using combined PET/CT by Bristow (2003)10.1200/JCO.1996.14.5.1545/ J Clin Oncol / Defining response of ovarian carcinoma to initial chemotherapy according to serum CA 125 by Rustin (1996)10.1093/oxfordjournals.annonc.a057754/ Ann Oncol / The role of CA 125 in the early diagnosis of progressive disease in ovarian cancer by van der Burg (1990)10.1023/A:1008240421028/ Ann Oncol / Predictors of response to subsequent chemotherapy in platinum pretreated ovarian cancer: a multivariate analysis of 704 patients by Eisenhauer (1997)10.1200/JCO.1993.11.3.434/ J Clin Oncol / Secondary cytoreduction for ovarian cancer following cisplatin therapy by Segna (1993)10.1016/S0029-7844(02)01977-4/ Obstet Gynecol / Secondary cytoreductive surgery for recurrent epithelial ovarian cancer by Tay (2002)- Feuer D, Broadley K. Surgery for the resolution of symptoms in malignant bowel obstruction in advanced gynaecological and gastrointestinal cancer. In: The Cochrame Library, Issue 3. Oxford: Update Software, 2003.
10.1038/bjc.1989.132/ Br J Cancer / Response of patients in phase II studies of chemotherapy in ovarian cancer: implications for patient treatment and the design of phase II trials by Blackledge (1989)10.1200/JCO.1991.9.10.1801/ J Clin Oncol / Responses to second-line cisplatin-based intraperitoneal therapy in ovarian cancer: influence of a prior response to intravenous cisplatin by Markman (1991){'key': '10.1016/j.clon.2005.05.009_bib128', 'series-title': 'The American Society of Clinical Oncology Educational Book', 'article-title': 'Treatment of relapsed ovarian cancer', 'author': 'Gore', 'year': '2001'}/ The American Society of Clinical Oncology Educational Book / Treatment of relapsed ovarian cancer by Gore (2001)10.1093/jnci/djh081/ J Natl Cancer Inst / Re: New guidelines to evaluate the response to treatment in solid tumors (ovarian cancer) by Rustin (2004)10.1093/annonc/mdf649/ Ann Oncol / Evaluation of response: new and standard criteria by Therasse (2002)10.1016/S0140-6736(03)13718-X/ Lancet / Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial by Parmar (2003)10.1200/JCO.20.5.1232/ J Clin Oncol / Randomized controlled trial of single-agent paclitaxel versus cyclophosphamide, doxorubicin, and cisplatin in patients with recurrent ovarian cancer who responded to first-line platinum-based regimens by Cantu (2002)10.1006/gyno.2001.6151/ Gynecol Oncol / Carboplatin alone vs carboplatin plus epidoxorubicin as second-line therapy for cisplatin- or carboplatin-sensitive ovarian cancer by Bolis (2001)-
Pfisterer J, Plante M, Vergote I, et al. Gemcitabine/carboplatin (GC) vs. carboplatin (C) in platinum sensitive recurrent ovarian cancer (OVCA). Results of a Gynecologic Cancer Intergroup randomized phase III trial of the AGO OVAR, the NCIC CTG and the EORTC GCG [abstract 5005]. ASCO Annual Meeting Proceedings (Post-Meeting Edition) 2004;22:14S.
(
10.1200/jco.2004.22.14_suppl.5005) 10.1200/JCO.1995.13.7.1584/ J Clin Oncol / Carboplatin reinduction after taxane in patients with platinum-refractory epithelial ovarian cancer by Kavanagh (1995)10.1200/JCO.1997.15.6.2183/ J Clin Oncol / Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer by ten Bokkel (1997)10.1200/JCO.2001.19.14.3312/ J Clin Oncol / Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan by Gordon (2001)10.1023/A:1013558501425/ Ann Oncol / Weekly cisplatin and oral etoposide as treatment for relapsed epithelial ovarian cancer by Meyer (2001)10.1038/sj.bjc.6600002/ Br J Cancer / Weekly cisplatin and daily oral etoposide is highly effective in platinum pretreated ovarian cancer by van der Burg (2002)10.1002/1097-0142(20001015)89:8<1783::AID-CNCR19>3.0.CO;2-D/ Cancer / Steroid hormone receptors and long term survival in invasive ovarian cancer by Munstedt (2000){'key': '10.1016/j.clon.2005.05.009_bib141', 'series-title': 'The Cochrane Library, Issue 3', 'article-title': 'Tamoxifen for relapse of ovarian cancer', 'author': 'Williams', 'year': '2003'}/ The Cochrane Library, Issue 3 / Tamoxifen for relapse of ovarian cancer by Williams (2003)10.1002/1097-0142(19910715)68:2<269::AID-CNCR2820680209>3.0.CO;2-O/ Cancer / Responsiveness of patients with advanced ovarian carcinoma to tamoxifen. A Gynecologic oncology group study of second-line therapy in 105 patients by Hatch (1991)10.1074/jbc.M103554200/ J Biol Chem / Molecular cloning of the CA125 ovarian cancer antigen: identification as a new mucin, MUC16 by Yin (2001){'key': '10.1016/j.clon.2005.05.009_bib144_1', 'first-page': '1112', 'article-title': 'Immunological consolidation of ovarian carcinoma recurrences with monoclonal anti-idiotype antibody ACA125: immune responses and survival in palliative treatment', 'volume': '7', 'author': 'Wagner', 'year': '2001', 'journal-title': 'Clin Cancer Res'}/ Clin Cancer Res / Immunological consolidation of ovarian carcinoma recurrences with monoclonal anti-idiotype antibody ACA125: immune responses and survival in palliative treatment by Wagner (2001){'key': '10.1016/j.clon.2005.05.009_bib144_2', 'first-page': '1154', 'volume': '7', 'year': '2001', 'journal-title': 'Clin Cancer Res'}/ Clin Cancer Res (2001)- Nicholson S, Bell S, McCormack M. et al. A randomised phase III trial of adjuvant Intraperitoneal Radioimmunotherapy in Ovarian cancer [abstract 1514]. 2000 ASCO Annual Meeting Proceedings.
10.1007/s00262-001-0255-1/ Cancer Immunol Immunother / Vaccination with autologous tumour antigen-pulsed dendritic cells in advanced gynaecological malignancies: clinical and immunological evaluation of a phase I trial by Hernando (2002){'key': '10.1016/j.clon.2005.05.009_bib147', 'first-page': '20', 'article-title': 'Evidence of p53 gene transfer and its biological activities in ovarian cancer patients receiving multiple cycles of recombinant adenovirus expressing wild-type p53', 'author': 'Fen Wen', 'year': '2001', 'journal-title': 'Proc Am Soc Clin Oncol'}/ Proc Am Soc Clin Oncol / Evidence of p53 gene transfer and its biological activities in ovarian cancer patients receiving multiple cycles of recombinant adenovirus expressing wild-type p53 by Fen Wen (2001)10.1016/S1470-2045(03)01139-2/ Lancet Oncol / Why did p53 gene therapy fail in ovarian cancer? by Zeimet (2003)10.1200/JCO.20.6.1562/ J Clin Oncol / Phase I trial of intraperitoneal injection of the E1B-55-kd-gene-deleted adenovirus ONYX-015 (dl1520) given on days 1 through 5 every 3 weeks in patients with recurrent/refractory epithelial ovarian cancer by Vasey (2002){'key': '10.1016/j.clon.2005.05.009_bib150', 'first-page': '5274', 'article-title': 'The “bystander effect”: tumor regression when a fraction of the tumor mass is genetically modified', 'volume': '53', 'author': 'Freeman', 'year': '1993', 'journal-title': 'Cancer Res'}/ Cancer Res / The “bystander effect”: tumor regression when a fraction of the tumor mass is genetically modified by Freeman (1993){'key': '10.1016/j.clon.2005.05.009_bib151', 'first-page': '20', 'article-title': 'Phase 2 evaluation of OS!-774, a potent oral antagonist of the EGFR-TK in patients with advanced ovarian carcinoma', 'author': 'Finkler', 'year': '2001', 'journal-title': 'Proc Am Soc Clin Oncol'}/ Proc Am Soc Clin Oncol / Phase 2 evaluation of OS!-774, a potent oral antagonist of the EGFR-TK in patients with advanced ovarian carcinoma by Finkler (2001)10.1038/sj.bjc.6600058/ Br J Cancer / Targeting the EGF receptor in ovarian cancer with the tyrosine kinase inhibitor ZD 1839 (“Iressa”) by Sewell (2002)10.1200/JCO.2003.10.104/ J Clin Oncol / Evaluation of monoclonal humanized anti-HER2 antibody, trastuzumab, in patients with recurrent or refractory ovarian or primary peritoneal carcinoma with overexpression of HER2: a phase II trial of the Gynecologic Oncology Group by Bookman (2003)10.1016/S0002-9440(10)64467-7/ Am J Pathol / Vascular endothelial growth factor immunoneutralization plus paclitaxel markedly reduces tumor burden and ascites in athymic mouse model of ovarian cancer by Hu (2002){'key': '10.1016/j.clon.2005.05.009_bib155', 'first-page': '2447', 'article-title': 'Therapeutic targeting of the endothelin a receptor in human ovarian carcinoma', 'volume': '63', 'author': 'Rosano', 'year': '2003', 'journal-title': 'Cancer Res'}/ Cancer Res / Therapeutic targeting of the endothelin a receptor in human ovarian carcinoma by Rosano (2003){'key': '10.1016/j.clon.2005.05.009_bib156', 'first-page': '4152', 'article-title': 'SU6668 is a potent antiangiogenic and antitumor agent that induces regression of established tumors', 'volume': '60', 'author': 'Laird', 'year': '2000', 'journal-title': 'Cancer Res'}/ Cancer Res / SU6668 is a potent antiangiogenic and antitumor agent that induces regression of established tumors by Laird (2000)10.1200/JCO.2002.20.4.1147/ J Clin Oncol / Ovarian and papillary-serous peritoneal carcinoma: pilot study with thalidomide by Abramson (2002)10.1054/bjoc.1999.1004/ Br J Cancer / Continuous low dose Thalidomide: a phase II study in advanced melanoma, renal cell, ovarian and breast cancer by Eisen (2000)10.1200/JCO.1998.16.2.405/ J Clin Oncol / Prolonged oral etoposide as second-line therapy for platinum-resistant and platinum-sensitive ovarian carcinoma: a Gynecologic Oncology Group study by Rose (1998)
@article{Guppy_2005, title={Epithelial Ovarian Cancer: A Review of Current Management}, volume={17}, ISSN={0936-6555}, url={http://dx.doi.org/10.1016/j.clon.2005.05.009}, DOI={10.1016/j.clon.2005.05.009}, number={6}, journal={Clinical Oncology}, publisher={Elsevier BV}, author={Guppy, A.E. and Nathan, P.D. and Rustin, G.J.S.}, year={2005}, month=sep, pages={399–411} }